Costs of the management of hemophilia A with inhibitors in Spain

Global & Regional Health Technology Assessment

卷:8

José Luis Poveda¹  Santiago Bonanad¹  María Teresa Álvarez²  Ramiro Núñez³  Beatriz Gil⁴  Elena Ruíz-Beato⁴  Almudena González-Domínguez⁵  Yoana Ivanova⁵  Inés Pérez-Román⁵  Ana Durán⁵ 

[1] Hospital Universitari i Politècnic La Fe, Valencia - Spain;

[2] Hospital Universitario La Paz, Madrid - Spain;

[3] Hospital Virgen del Rocío, Sevilla - Spain;

[4] Roche Farma, Madrid - Spain;

[5] Weber, Madrid - Spain;

关键词: Activated prothrombin complex concentrate;    Costs;    Emicizumab;    Hemophilia A;    Recombinant factor VIIa;   

DOI  :  10.33393/grhta.2021.2234

来源: DOAJ

【 摘 要 】

Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in adult and pediatric patients, including the prophylaxis with emicizumab.Methods: We calculated the costs of the on-demand and prophylactic treatments with bypassing agents (activated prothrombin complex concentrate and recombinant activated factor VII) and the emicizumab prophylaxis, from the societal perspective, over 1 year. The study considered direct healthcare costs (drugs, visits, tests, and hospitalizations), direct non-healthcare costs (informal caregivers), and indirect costs (productivity loss). Data were obtained from a literature review and were validated by an expert group. Costs were expressed in 2019 euros.Results: Our results showed that the annual costs of the prophylactic treatment per patient varied between €543,062.99 and €821,415.77 for adults, and €182,764.43 and €319,826.59 for children, while on-demand treatment was €532,706.84 and €789,341.91 in adults, and €167,523.05 and €238,304.71 in pediatric patients. In relation to other prophylactic therapies, emicizumab showed the lowest costs, with up to a 34% and 43% reduction in the management cost of adult and pediatric patients, respectively. It reduced the bleeding events and administration costs, as this drug is less frequently administered by subcutaneous route. Emicizumab prophylaxis also decreased the cost of other healthcare resources such as visits, tests, and hospitalizations, as well as indirect costs.Conclusion: In comparison to prophylaxis with bypassing agents, emicizumab reduced direct and indirect costs, resulting in cost savings for the National Health System and society.

【 授权许可】

Unknown